Nefecon for IgA Nephropathy in China: 2-Year Results
Author Information
Author(s): Zhang Hong, Lafayette Richard, Wang Bei, Ying Lisa, Zhu Zhengying, Stone Andrew, Kristensen Jens, Barratt Jonathan
Primary Institution: Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China
Hypothesis
Does nefecon treatment lead to better kidney function preservation in patients with IgA nephropathy compared to placebo?
Conclusion
Nefecon treatment for 9 months resulted in better preservation of kidney function over 2 years compared to placebo.
Supporting Evidence
- Patients treated with nefecon had a 9.6 ml/min per 1.73 m2 improvement in eGFR compared to placebo.
- Only 9% of nefecon patients experienced a confirmed 30% eGFR reduction compared to 30% in the placebo group.
- Nefecon treatment led to a 31% greater reduction in proteinuria at 9 months compared to placebo.
Takeaway
This study shows that a new medicine called nefecon helps keep kidneys working better for people with a specific kidney disease called IgA nephropathy.
Methodology
Patients with IgA nephropathy received nefecon or placebo for 9 months, followed by 15 months of supportive care.
Potential Biases
No specific risks of bias were mentioned.
Limitations
The study had a small sample size and was not independently powered for the China cohort.
Participant Demographics
Participants were primarily Asian, with a median age of 38 years and a balanced male-to-female ratio.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI, 2.0 to 19.8
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website